Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1834845 and BAY 1830839 in healthy men using imiquimod skin inflammation and intravenous lipopolysaccharide challenge models
NL-OMON50967Completed
- Sponsor
- Bayer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of zabedosertib and BAY1830839 in contact dermatitis (4 arms), sponsored by Bayer. Primary endpoints: Average change of perfusion/basal flow and erythema and Average change in systemic inflammation markers. Started Jun 2021; status: completed.
02
Drugs
zabedosertibBAY1830839
03
Conditions
contact dermatitis
Beyond the preview
Go deeper on NL-OMON50967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50967.